A citation-based method for searching scientific literature

Ele Ferrannini, Silvia Jimenez Ramos, Afshin Salsali, Weihua Tang, James F List. Diabetes Care 2010
Times Cited: 493



R R Henry, A V Murray, M H Marmolejo, D Hennicken, A Ptaszynska, J F List. Int J Clin Pract 2012
Times Cited: 207




List of shared articles



Times cited

Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
Eiichi Araki, Hirotaka Watada, Yasuko Uchigata, Osamu Tomonaga, Hitomi Fujii, Hiroshi Ohashi, Tadashi Okabe, Michiko Asano, Fredrik Thoren, Hyosung Kim,[...]. Diabetes Obes Metab 2020
9


Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Tobias Täger, Dan Atar, Stefan Agewall, Hugo A Katus, Morten Grundtvig, John G F Cleland, Andrew L Clark, Hanna Fröhlich, Lutz Frankenstein. Heart Fail Rev 2020
7




Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers.
Hiddo J L Heerspink, C David Sjöström, Silvio E Inzucchi, Melissa K Hallow, Valerie A Cain, Peter Rossing, Bergur V Stefansson, Peter Sartipy. Diabetes Obes Metab 2019
9

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study.
Anna Norhammar, Johan Bodegård, Thomas Nyström, Marcus Thuresson, David Nathanson, Jan W Eriksson. Diabetes Obes Metab 2019
38

Combination Therapy with an SGLT2 Inhibitor as Initial Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Tamara Y Milder, Sophie L Stocker, Christina Abdel Shaheed, Lucy McGrath-Cadell, Dorit Samocha-Bonet, Jerry R Greenfield, Richard O Day. J Clin Med 2019
19

Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Xiaoling Cai, Lizheng Shi, Wenjia Yang, Shuyan Gu, Yingyao Chen, Lin Nie, Linong Ji. J Med Econ 2019
7

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
73


Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
60

Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea.
Sang Hyun Park, Young Ju Choi, Eun Jung Rhee, Kab Bum Huh. Endocrinol Metab (Seoul) 2019
0

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control.
Manash Pratim Baruah, B M Makkar, Vikrant B Ghatnatti, Kaushik Mandal. Indian J Endocrinol Metab 2019
5

Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Surender Kumar, Pradeep G Talwalkar, Sambit Das, Soumik Goswami. Indian J Endocrinol Metab 2019
1

Assessment of Dapagliflozin Effectiveness as Add-on Therapy for the Treatment of Type 2 Diabetes Mellitus in a Qatari Population.
Rana Moustafa Al AdAwi, Zainab Jassim, Dina Elgaily, Hani Abdelaziz, Bhagya Sree, Mohamed Izham Mohamed Ibrahim. Sci Rep 2019
4